Compare Recursion Pharmaceuticals Inc (RXRX) vs Yum! Brands, Inc. (YUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Yum! Brands, Inc. — how do they compare? Recursion Pharmaceuticals Inc trades at $3.23 (market cap $1.86B), while Yum! Brands, Inc. trades at $144.94 (market cap $40.80B). The key difference: Yum! Brands, Inc. is far larger — about 21.9× Recursion Pharmaceuticals Inc's market cap, and Yum! Brands, Inc. pays a 2.01% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | YUM | |
|---|---|---|
Market Cap | $1.86B | $40.80B |
Sector | Health | Consumer Cyclical |
52-Week High | $6.79 | $168.16 |
52-Week Low | $2.84 | $138.21 |
Enterprise Value | $1.38B | $52.40B |
Dividend Yield | — | 2.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
YUM trades at $149.59, down 0.74% on the day, with a bearish technical signal and neutral oscillators. The company reported revenue of $8.21B and net income of $1.56B in 2025, with a P/E ratio of 18.83. Recent developments include the sale of Pizza Hut for approximately $1.5B to LongRange Capital, with proceeds aimed at debt reduction and share buybacks, alongside a declared $0.75 quarterly dividend.
The outlook is mixed: analyst consensus is a buy with a $173.60 price target, but high debt and a legal investigation pose risks. Earnings have beaten expectations in two of the last three quarters, with Q3 2026 results pending. The stock offers potential upside from strategic refocusing and buybacks, balanced against consumer spending pressures and leverage concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Yum! Brands, Inc.
Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (26,930 global units), Pizza Hut (18,380 units), Taco Bell (7,790 units), and The Habit Burger (310 units) at year-end 2021. With $58 billion in 2021 systemwide sales, the firm is the second-largest restaurant company in the world, behind McDonald's ($112.5 billion) but ahead of Restaurant Brands International ($36 billion) and Starbucks ($25 billion). Yum is 98% franchised, with the largest franchisee, Yum China, created via a 2016 spinoff transaction (after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity). Yum is the newest evolution of Tricon Brands, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.
Read more on YUM →
